Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
10:41am, Monday, 04'th Jan 2021
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer's Disease Agitation
06:15am, Thursday, 31'st Dec 2020
ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation
Over 21,000 migraine attacks treated with AXS-07
Several High Impact Catalysts For Axsome In H1 2021
07:51am, Wednesday, 23'rd Dec 2020
The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 readout
68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
06:00am, Wednesday, 02'nd Dec 2020
R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment
R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
11:56am, Thursday, 05'th Nov 2020
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization™ Platform
07:03am, Wednesday, 04'th Nov 2020
Collaboration provides Axsome access to new digital technologies developed by Veeva
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
07:00am, Wednesday, 28'th Oct 2020
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time
IPO Update: Harmony Biosciences Seeks $100 Million IPO (Pending:HRMY)
09:45pm, Tuesday, 11'th Aug 2020
Harmony Biosciences intends to raise $100 million in an IPO. The firm is developing and commercializing treatments for narcolepsy and related conditions.
Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses
05:05pm, Tuesday, 11'th Aug 2020
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.
Why Axsome Therapeutics Stock Rose Today
08:44pm, Monday, 10'th Aug 2020
The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
11:05am, Monday, 10'th Aug 2020
Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020 Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3 lon
